Sellas Life Sciences Increases Stake and Seeks Shareholder Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLS?
Source: stocktwits
- Stake Increase: Commonwealth Equity Services raised its stake in Sellas Life Sciences by 32%, adding 9,226 shares to total holdings of 38,470 shares valued at approximately $162,730, indicating strong confidence in the company's cancer drug development.
- CEO Reaffirms Confidence: CEO Angelos Stergiou stated that his confidence in the commercial potential of the REGAL trial remains unchanged despite the trial being blinded, with expectations for database lock and statistical analysis once 80 overall survival events are recorded.
- Shareholder Plan Expansion: Sellas is seeking shareholder approval to increase its share reserve under the 2023 Amended Equity Incentive Plan by 20 million shares, addressing the limited availability of only 7,991 shares for future awards under the existing plan.
- Positive Market Sentiment: On Stocktwits, retail sentiment for SLS is deemed 'bullish', with users expressing confidence that institutional players like BlackRock will support the shareholder plan, reflecting strong market optimism towards Sellas.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.460
Low
7.00
Averages
7.25
High
7.50
Current: 4.460
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sellas Life Sciences Increases Stake and Seeks Shareholder Approval
- Stake Increase: Commonwealth Equity Services raised its stake in Sellas Life Sciences by 32%, adding 9,226 shares to total holdings of 38,470 shares valued at approximately $162,730, indicating strong confidence in the company's cancer drug development.
- CEO Reaffirms Confidence: CEO Angelos Stergiou stated that his confidence in the commercial potential of the REGAL trial remains unchanged despite the trial being blinded, with expectations for database lock and statistical analysis once 80 overall survival events are recorded.
- Shareholder Plan Expansion: Sellas is seeking shareholder approval to increase its share reserve under the 2023 Amended Equity Incentive Plan by 20 million shares, addressing the limited availability of only 7,991 shares for future awards under the existing plan.
- Positive Market Sentiment: On Stocktwits, retail sentiment for SLS is deemed 'bullish', with users expressing confidence that institutional players like BlackRock will support the shareholder plan, reflecting strong market optimism towards Sellas.
See More
Markets Retreat as Investors Await Fed Decision and Big Tech Earnings
- Cautious Market Sentiment: U.S. stock futures retreated from record highs as investors tread carefully ahead of the Fed's rate decision and major tech earnings, with Nasdaq futures down 0.5% and S&P 500 futures slipping 0.3%.
- Geopolitical Impact: Renewed tensions in the Middle East have driven Brent crude prices above $110, reflecting market concerns over supply disruptions, while gold has slipped to a three-week low, indicating mixed safe-haven positioning among investors.
- Tech Stock Dynamics: Retail sentiment towards the SPDR S&P 500 ETF (SPY) has shifted back to 'bullish', while the Invesco QQQ Trust (QQQ) remains 'bearish', highlighting a divergence in market sentiment as the tech sector approaches a critical earnings period.
- Stocks to Watch: Nvidia (NVDA) has reached a new high driven by AI momentum, solidifying its position as the world's most valuable company, while Bed Bath & Beyond (BBBY) is trending after reporting its first quarterly revenue growth in five years, attracting retail interest.
See More
Sellas CEO Reaffirms Confidence in Phase 3 Regal Trial Amidst Market Volatility
- Confidence in Regal Trial: Sellas Life Sciences CEO Angelos Stergiou expressed steadfast confidence in the commercial prospects of the Regal trial despite its blinded status, with final analysis expected after 80 overall survival events are recorded, which could enhance the company's market position in acute myeloid leukemia (AML).
- SLS009 Clinical Updates: Stergiou highlighted 2026 as a pivotal year for the CDK9 inhibitor SLS009, urging investors to look for clinical updates and top-line data from ongoing Phase 2 studies this year, with recent lab findings indicating promising effects in hard-to-treat AML cases, potentially boosting the company's future market performance.
- Equity Incentive Plan Expansion: Stergiou is seeking approval to increase the share reserve under the 2023 Amended Equity Incentive Plan by 20 million shares, as only 7,991 shares remain available for future awards, and approval would facilitate executive incentives and attract more investor interest in the company's long-term growth.
- Institutional Investor Participation: Ahead of expected clinical milestones, BlackRock disclosed a 6.8% stake in Sellas, indicating growing confidence among institutional investors, while Dagco increased its holdings by 78%, further solidifying Sellas's appeal in the healthcare investment landscape.
See More
Sellas Life Sciences' SLS009 Drug Update Fails to Meet Expectations
- Drug Update Miss: Sellas Life Sciences' anticipated update on its leukemia drug SLS009 did not materialize, leading to a nearly 1% drop in after-hours trading, reflecting diminished investor sentiment and focus on the company's cancer pipeline.
- Clinical Trial Insights: Earlier studies indicated that SLS009 could induce leukemia cell death and remained effective in difficult-to-treat AML cases with ASXL1 and TP53 mutations; however, the lack of recent updates has left investors anxious about its future performance.
- China Milestone Payment Dispute: Attention has shifted to an arbitration proceeding with Chinese partner 3D Medicines regarding development and commercialization rights for 3D189 and milestone payments related to SLS009, which could impact future cash flows and project timelines.
- Regal Trial Focus: Investor interest in the ongoing Phase 3 Regal trial is increasing, with 72 survival events recorded, nearing the 80-event threshold required for topline analysis, and despite the absence of updates, the market remains hopeful that trial results will positively influence the company's stock price.
See More
Dagco Increases Sellas Stake to 1.01% Ahead of Key Data
- Stake Increase: Dagco added 451,240 shares of Sellas Life Sciences on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million, making it the second-largest holding at 1.01% of its portfolio, indicating strong confidence in Sellas' future prospects.
- Clinical Data Catalyst: Sellas is set to present preclinical data on SLS009 at the AACR conference, targeting acute myeloid leukemia (AML), with lab studies showing that it induces leukemia cell death by enhancing caspase-3 activity, potentially offering new treatment options for AML patients.
- Regal Trial Progress: The Phase 3 Regal trial has recorded 72 survival events, moving closer to the 80-event threshold for final analysis, with the CEO suggesting that the slower accumulation of events may indicate longer patient survival, further heightening investor expectations.
- Optimistic Market Sentiment: Retail sentiment for SLS on Stocktwits is deemed 'extremely bullish' amid high message volume, with investors generally optimistic about the potential of SLS009, reflecting positive market expectations for Sellas' future developments.
See More
SLS and ATNM Present Key Data Catalysts Ahead of AACR Summit
- Optimistic Outlook for SLS009: Sellas is set to present preclinical AML data on SLS009 at the AACR meeting, demonstrating significant increases in cancer cell death in models with ASXL1 and TP53 mutations, which could attract investor attention and drive stock price appreciation.
- ATNM Data Highlights: Actinium will showcase new data from its Actinium-225 radiotherapy platform at AACR, particularly regarding ATNM-400 and Actimab-A across leukemia and solid tumor programs, potentially boosting market confidence in its treatment options.
- Analyst Target Discrepancies: According to consensus estimates from Koyfin, ATNM has a 12-month average analyst price target of $5.75, implying a 342% upside, while SLS's target is $8.67, suggesting about 66% upside, indicating a higher appeal for ATNM among investors.
- Retail Sentiment Comparison: On Stocktwits, retail sentiment for ATNM is deemed 'extremely bullish', while SLS appears 'bearish', which may influence investor decisions and market performance.
See More
Sellas Life Sciences Increases Stake and Seeks Shareholder Approval
- Stake Increase: Commonwealth Equity Services raised its stake in Sellas Life Sciences by 32%, adding 9,226 shares to total holdings of 38,470 shares valued at approximately $162,730, indicating strong confidence in the company's cancer drug development.
- CEO Reaffirms Confidence: CEO Angelos Stergiou stated that his confidence in the commercial potential of the REGAL trial remains unchanged despite the trial being blinded, with expectations for database lock and statistical analysis once 80 overall survival events are recorded.
- Shareholder Plan Expansion: Sellas is seeking shareholder approval to increase its share reserve under the 2023 Amended Equity Incentive Plan by 20 million shares, addressing the limited availability of only 7,991 shares for future awards under the existing plan.
- Positive Market Sentiment: On Stocktwits, retail sentiment for SLS is deemed 'bullish', with users expressing confidence that institutional players like BlackRock will support the shareholder plan, reflecting strong market optimism towards Sellas.
See More
Markets Retreat as Investors Await Fed Decision and Big Tech Earnings
- Cautious Market Sentiment: U.S. stock futures retreated from record highs as investors tread carefully ahead of the Fed's rate decision and major tech earnings, with Nasdaq futures down 0.5% and S&P 500 futures slipping 0.3%.
- Geopolitical Impact: Renewed tensions in the Middle East have driven Brent crude prices above $110, reflecting market concerns over supply disruptions, while gold has slipped to a three-week low, indicating mixed safe-haven positioning among investors.
- Tech Stock Dynamics: Retail sentiment towards the SPDR S&P 500 ETF (SPY) has shifted back to 'bullish', while the Invesco QQQ Trust (QQQ) remains 'bearish', highlighting a divergence in market sentiment as the tech sector approaches a critical earnings period.
- Stocks to Watch: Nvidia (NVDA) has reached a new high driven by AI momentum, solidifying its position as the world's most valuable company, while Bed Bath & Beyond (BBBY) is trending after reporting its first quarterly revenue growth in five years, attracting retail interest.
See More
Sellas CEO Reaffirms Confidence in Phase 3 Regal Trial Amidst Market Volatility
- Confidence in Regal Trial: Sellas Life Sciences CEO Angelos Stergiou expressed steadfast confidence in the commercial prospects of the Regal trial despite its blinded status, with final analysis expected after 80 overall survival events are recorded, which could enhance the company's market position in acute myeloid leukemia (AML).
- SLS009 Clinical Updates: Stergiou highlighted 2026 as a pivotal year for the CDK9 inhibitor SLS009, urging investors to look for clinical updates and top-line data from ongoing Phase 2 studies this year, with recent lab findings indicating promising effects in hard-to-treat AML cases, potentially boosting the company's future market performance.
- Equity Incentive Plan Expansion: Stergiou is seeking approval to increase the share reserve under the 2023 Amended Equity Incentive Plan by 20 million shares, as only 7,991 shares remain available for future awards, and approval would facilitate executive incentives and attract more investor interest in the company's long-term growth.
- Institutional Investor Participation: Ahead of expected clinical milestones, BlackRock disclosed a 6.8% stake in Sellas, indicating growing confidence among institutional investors, while Dagco increased its holdings by 78%, further solidifying Sellas's appeal in the healthcare investment landscape.
See More
Sellas Life Sciences' SLS009 Drug Update Fails to Meet Expectations
- Drug Update Miss: Sellas Life Sciences' anticipated update on its leukemia drug SLS009 did not materialize, leading to a nearly 1% drop in after-hours trading, reflecting diminished investor sentiment and focus on the company's cancer pipeline.
- Clinical Trial Insights: Earlier studies indicated that SLS009 could induce leukemia cell death and remained effective in difficult-to-treat AML cases with ASXL1 and TP53 mutations; however, the lack of recent updates has left investors anxious about its future performance.
- China Milestone Payment Dispute: Attention has shifted to an arbitration proceeding with Chinese partner 3D Medicines regarding development and commercialization rights for 3D189 and milestone payments related to SLS009, which could impact future cash flows and project timelines.
- Regal Trial Focus: Investor interest in the ongoing Phase 3 Regal trial is increasing, with 72 survival events recorded, nearing the 80-event threshold required for topline analysis, and despite the absence of updates, the market remains hopeful that trial results will positively influence the company's stock price.
See More
Dagco Increases Sellas Stake to 1.01% Ahead of Key Data
- Stake Increase: Dagco added 451,240 shares of Sellas Life Sciences on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million, making it the second-largest holding at 1.01% of its portfolio, indicating strong confidence in Sellas' future prospects.
- Clinical Data Catalyst: Sellas is set to present preclinical data on SLS009 at the AACR conference, targeting acute myeloid leukemia (AML), with lab studies showing that it induces leukemia cell death by enhancing caspase-3 activity, potentially offering new treatment options for AML patients.
- Regal Trial Progress: The Phase 3 Regal trial has recorded 72 survival events, moving closer to the 80-event threshold for final analysis, with the CEO suggesting that the slower accumulation of events may indicate longer patient survival, further heightening investor expectations.
- Optimistic Market Sentiment: Retail sentiment for SLS on Stocktwits is deemed 'extremely bullish' amid high message volume, with investors generally optimistic about the potential of SLS009, reflecting positive market expectations for Sellas' future developments.
See More
SLS and ATNM Present Key Data Catalysts Ahead of AACR Summit
- Optimistic Outlook for SLS009: Sellas is set to present preclinical AML data on SLS009 at the AACR meeting, demonstrating significant increases in cancer cell death in models with ASXL1 and TP53 mutations, which could attract investor attention and drive stock price appreciation.
- ATNM Data Highlights: Actinium will showcase new data from its Actinium-225 radiotherapy platform at AACR, particularly regarding ATNM-400 and Actimab-A across leukemia and solid tumor programs, potentially boosting market confidence in its treatment options.
- Analyst Target Discrepancies: According to consensus estimates from Koyfin, ATNM has a 12-month average analyst price target of $5.75, implying a 342% upside, while SLS's target is $8.67, suggesting about 66% upside, indicating a higher appeal for ATNM among investors.
- Retail Sentiment Comparison: On Stocktwits, retail sentiment for ATNM is deemed 'extremely bullish', while SLS appears 'bearish', which may influence investor decisions and market performance.
See More
